113 related articles for article (PubMed ID: 2162976)
1. Growth fractions of breast cancer in relation to epidermal growth factor receptor and estrogen receptor.
Toi M; Wada T; Yamada H; Ohsaki A; Yamamoto A; Nakamura T; Niimoto M; Hattori T
Jpn J Surg; 1990 May; 20(3):327-30. PubMed ID: 2162976
[TBL] [Abstract][Full Text] [Related]
2. In situ distribution of oncogene products and growth factor receptors in breast carcinoma: c-erbB-2 oncoprotein, EGFr, and PDGFr-beta-subunit.
Kommoss F; Colley M; Hart CE; Franklin WA
Mol Cell Probes; 1990 Feb; 4(1):11-23. PubMed ID: 1969111
[TBL] [Abstract][Full Text] [Related]
3. EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast.
Lebeau A; Unholzer A; Amann G; Kronawitter M; Bauerfeind I; Sendelhofert A; Iff A; Löhrs U
Breast Cancer Res Treat; 2003 May; 79(2):187-98. PubMed ID: 12825853
[TBL] [Abstract][Full Text] [Related]
4. Immunocytochemical and biochemical analysis of epidermal growth factor receptor expression in human breast cancer tissues: relationship to estrogen receptor and lymphatic invasion.
Toi M; Hamada Y; Nakamura T; Mukaida H; Suehiro S; Wada T; Toge T; Niimoto M; Hattori T
Int J Cancer; 1989 Feb; 43(2):220-5. PubMed ID: 2645219
[TBL] [Abstract][Full Text] [Related]
5. Studies of epidermal growth factor receptor inhibition in breast cancer.
Bundred NJ; Chan K; Anderson NG
Endocr Relat Cancer; 2001 Sep; 8(3):183-9. PubMed ID: 11566609
[TBL] [Abstract][Full Text] [Related]
6. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
7. Expression of epidermal growth factor receptors (EGFR) on breast carcinomas in relation to growth fractions, estrogen receptor status and morphological criteria. An immunohistochemical study.
Wrba F; Reiner A; Ritzinger E; Holzner JH; Reiner G
Pathol Res Pract; 1988 Feb; 183(1):25-9. PubMed ID: 3362749
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical demonstration of cell proliferation and estrogen receptor status in human breast cancer. Analysis of 45 cases.
Hori M; Furusato M; Nikaidoh T; Aizawa S
Acta Pathol Jpn; 1990 Dec; 40(12):902-7. PubMed ID: 1965755
[TBL] [Abstract][Full Text] [Related]
9. Comparison of estrogen receptor and epidermal growth factor receptor content of primary and involved nodes in human breast cancer.
Mori T; Morimoto T; Komaki K; Monden Y
Cancer; 1991 Aug; 68(3):532-7. PubMed ID: 2065272
[TBL] [Abstract][Full Text] [Related]
10. [Comparative study on estrogen receptor, epidermal growth factor and epidermal growth factor receptor using immunocytochemical and biochemical assays in breast cancer].
Toi M
Nihon Geka Gakkai Zasshi; 1988 May; 89(5):725-36. PubMed ID: 3261831
[TBL] [Abstract][Full Text] [Related]
11. Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction.
Domagala W; Lasota J; Bartkowiak J; Weber K; Osborn M
Am J Pathol; 1990 Jan; 136(1):219-27. PubMed ID: 2153347
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptors in human breast and endometrial carcinomas.
Llorens MA; Bermejo MJ; Salcedo MC; Charro AL; Puente M
J Steroid Biochem; 1989; 34(1-6):505-9. PubMed ID: 2626045
[TBL] [Abstract][Full Text] [Related]
13. Relationship between epidermal growth factor receptor status and various prognostic factors in human breast cancer.
Toi M; Nakamura T; Mukaida H; Wada T; Osaki A; Yamada H; Toge T; Niimoto M; Hattori T
Cancer; 1990 May; 65(9):1980-4. PubMed ID: 2372767
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
[TBL] [Abstract][Full Text] [Related]
15. Dual immunocytochemical analysis of oestrogen and epidermal growth factor receptors in human breast cancer.
Sharma AK; Horgan K; Douglas-Jones A; McClelland R; Gee J; Nicholson R
Br J Cancer; 1994 Jun; 69(6):1032-7. PubMed ID: 8198966
[TBL] [Abstract][Full Text] [Related]
16. Id4 messenger RNA and estrogen receptor expression: inverse correlation in human normal breast epithelium and carcinoma.
de Candia P; Akram M; Benezra R; Brogi E
Hum Pathol; 2006 Aug; 37(8):1032-41. PubMed ID: 16867866
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.
Umemura S; Takekoshi S; Suzuki Y; Saitoh Y; Tokuda Y; Osamura RY
Oncol Rep; 2005 Aug; 14(2):337-43. PubMed ID: 16012712
[TBL] [Abstract][Full Text] [Related]
18. Oestrogen receptor negativity as a marker for high-grade ductal carcinoma in situ of the breast.
Baqai T; Shousha S
Histopathology; 2003 May; 42(5):440-7. PubMed ID: 12713620
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers.
Wernicke AG; Varma S; Greenwood EA; Christos PJ; Chao KS; Liu H; Bander NH; Shin SJ
APMIS; 2014 Jun; 122(6):482-9. PubMed ID: 24304465
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of epidermal growth factor receptor (EGFR) in breast cancer patients. Results of a follow-up study on 149 patients.
Railo MJ; Smitten KV; Pekonen F
Acta Oncol; 1994; 33(1):13-7. PubMed ID: 8142117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
